Leary, Jacob B.
Enright, Thomas
Bakaloudi, Dimitra Rafailia
Basnet, Alina
Bratslavsky, Gennady
Jacob, Joseph
Spiess, Philippe E.
Li, Roger
Necchi, Andrea
Kamat, Ashish M.
Pavlick, Dean C.
Danziger, Natalie
Huang, Richard S. P.
Lin, Douglas I.
Cheng, Liang
Ross, Jeffrey
Talukder, Rafee
Grivas, Petros http://orcid.org/0000-0003-3965-3394
Article History
Accepted: 14 March 2024
First Online: 3 April 2024
Declarations
:
: No external funding was used in the preparation of this manuscript.
: J.B.L., T.E., D.R.B., A.B., and R.T. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. G.B.: no financial interests; member of NCI GU Steering Committee, Renal Task Force. J.J.: has served in a consulting/advisory role for Janssen and Pfizer. P.E.S.: no financial interests; Vice Chair of NCCN Bladder and Penile Cancer Panel. R.L.: has received research support from Predicine, Veracyte, CG Oncology, Valar Labs, and Merck; serves on clinical trial protocol committees for CG Oncology, Merck, and Janssen and has served in a consulting/advisory role for Bristol Myers Squibb, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence, CG Oncology, and Janssen. A.N.: has received honoraria from Roche, MSD, AstraZeneca, Janssen, Foundation Medicine, Bristol Myers Squibb, and Astellas Pharma; has served in a consulting or advisory role for MSD, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol Myers Squibb, Rainier Therapeutics, Bicycle Therapeutics, GlaxoSmithKline, Basilea Pharmaceutica, and Catalym; has received research funding from MSD, AstraZeneca, Ipsen, and Gilead; has received travel, accommodations, and expenses from Roche, MSD, AstraZeneca, Janssen, Rainer Therapeutics, and Pfizer; and has employment and stock ownership (spouse) in Bayer. A.M.K.: has grants or contracts from FKD Therapies (now Ferring), Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostics, and SWOG; has roles on advisory board or has received consulting fees from Astellas Pharma, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Imagin Medical, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma Therapeutics), Theralase, Urogen Pharma, US Biotest, and Vivet Therapeutics; holds patent for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy), a joint patent with MD Anderson Cancer Center; and has leadership or fiduciary roles at European Urology Oncology, International Bladder Cancer Group (IBCG), International Bladder Cancer Network (IBCN), Journal of Urology, and UroToday. D.C.P., N.D., R.S.P.H., D.I.L. are employees of Foundation Medicine Inc., a wholly owned subsidiary of Roche, and receive equity from Roche. J.R. is an employee of Foundation Medicine Inc., a wholly owned subsidiary of Roche and receives equity from Roche, and has served in a consulting role for Tango Therapeutics and Celsius Therapeutics. P.G.: has served in a consulting role for 4D Pharma, Aadi Bioscience, Abbvie, Asieris Pharmaceuticals, Astellas, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, G1 Therapeutics, Genentech, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, PureTech, QED Therapeutics, Regeneron, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, and UroGen Pharma; has received research funding from ALX Oncology, Acrivon Therapeutics, Bavarian Nordic, Bristol Myers Squibb, Debiopharm Group, Genentech, G1 Therapeutics, Gilead Sciences, GSK, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, and QED Therapeutics.
: Approval for this study, including a waiver of informed consent and a HIPAA waiver of authorization, was obtained from the Western Institutional Review Board (protocol no. 20152817) given the retrospective nature of this clinical study and deidentification was ensured for each tumor sample. The study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: A waiver of informed consent and a HIPAA waiver of authorization was obtained from the Western Institutional Review Board (protocol no. 20152817) given the retrospective nature of this clinical study.
: Not applicable.
: Data are available on request from the authors.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by D.C.P., D.R.B., and R.T. The first draft of the manuscript was written by J.B.L. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.